Table 8.
Using Thyroglobulin and Response to Initial Therapy Assessments at the 2-Year Follow-Up Time Point to Predict Likelihood of Being No Clinical Evidence of Disease at Final Follow-Up
| Initial risk stratification | Response to therapy variables during first 2 years of follow-up | NED at final follow-up |
|---|---|---|
| Low risk (n = 104) | Suppressed Tg < 1 ng/mL alone | 84% |
| Stimulated Tg < 1 ng/mL alone | 89% | |
| Excellent response (imaging negativea and suppressed Tg < 1 ng/mL) | 94% | |
| Excellent response (imaging negativea and stimulated Tg < 1 ng/mL) | 97% | |
| Intermediate risk (n = 241) | Suppressed Tg < 1 ng/mL alone | 74% |
| Stimulated Tg < 1 ng/mL alone | 80% | |
| Excellent response (imaging negativea and suppressed Tg < 1 ng/mL) | 90% | |
| Excellent response (imaging negativea and stimulated Tg < 1 ng/mL) | 94% | |
| High risk (n = 126) | Suppressed Tg < 1 ng/mL alone | 39% |
| Stimulated Tg < 1 ng/mL alone | 55% | |
| Excellent response (imaging negativea and suppressed Tg < 1 ng/mL) | 80% | |
| Excellent response (imaging negativea and stimulated Tg < 1 ng/mL) | 82% |
n = 471 with both suppressed and stimulated Tg values available for analysis.
a
Negative imaging: normal neck US in all patients. In addition, any other functional or cross-sectional imaging obtained at the discretion of the treating physician was interpreted as having no evidence of persistent/recurrent thyroid cancer.
NED, no clinical evidence of disease.